Of note, at least 12 dropout genes, including BRD4, that were essential to at least three AML cell lines, as well as to HT-29 and HT-1080, are targets of clinical inhibitors (Table S4), indicating that “pan-essential” genes should not be dismissed as potential therapeutic targets. The gene discussed is BRD4; the disease is acute myeloid leukemia.